NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $4.23 +0.08 (+1.93%) (As of 10:57 AM ET) Add Compare Share Share Today's Range$4.11▼$4.2350-Day Range$1.78▼$4.2352-Week Range$1.05▼$4.30Volume42,590 shsAverage Volume241,565 shsMarket Capitalization$264.59 millionP/E RatioN/ADividend YieldN/APrice Target$5.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Corvus Pharmaceuticals alerts: Email Address Corvus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside22.1% Upside$5.17 Price TargetShort InterestHealthy1.84% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.09Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.49) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.83 out of 5 starsMedical Sector639th out of 924 stocksPharmaceutical Preparations Industry290th out of 426 stocks 2.3 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has received no research coverage in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.84% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 8.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 3.9 News and Social Media Coverage News SentimentCorvus Pharmaceuticals has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.Search Interest5 people have searched for CRVS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows2 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.49) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 5.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corvus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More CRVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVS Stock News HeadlinesAugust 20 at 2:20 PM | investing.comCorvus Pharmaceuticals Inc (CRVS)August 20 at 1:54 AM | americanbankingnews.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in JulyAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 6, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 1, 2024 | marketwatch.comCorvus Pharma Gets FDA's Fast-Track for Lymphoma TreatmentAugust 1, 2024 | globenewswire.comCorvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)July 31, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024May 31, 2024 | investorplace.comThe 2024 Millionaire's Club: 3 Penny Stocks to Buy NowAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.May 30, 2024 | globenewswire.comCorvus Pharmaceuticals to Present at the Jefferies Global Health ConferenceMay 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Corvus Pharmaceuticals, Inc. (CRVS) and Encourages Investors to Contact the FirmMay 12, 2024 | finance.yahoo.com13 Penny Stocks with Insider Buying in 2024May 10, 2024 | finance.yahoo.comInsider Spends US$1m Buying More Shares In Corvus PharmaceuticalsMay 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comQ1 2024 Corvus Pharmaceuticals Inc Earnings CallMay 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 6, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsSee More Headlines Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$5.17 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+24.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.96% Return on Assets-50.83% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book5.25Miscellaneous Outstanding Shares62,551,000Free Float42,973,000Market Cap$259.59 million OptionableOptionable Beta1.11 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Richard A. Miller M.D. (Age 73)Co-Founder, President, CEO & Chairman of the Board Comp: $116.31kDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Director Comp: $47kMr. Leiv Lea (Age 70)Chief Financial Officer Comp: $400.21kDr. William Benton Jones Ph.D. (Age 58)Senior Vice President of Pharmaceutical Development Comp: $355.7kDr. James T. Rosenbaum M.D.Senior Vice President of ResearchMr. Jeffrey S. ArcaraChief Business OfficerMore ExecutivesKey CompetitorsOrgenesisNASDAQ:ORGSEnlivex TherapeuticsNASDAQ:ENLVAytu BioPharmaNASDAQ:AYTUXencorNASDAQ:XNCRGyre TherapeuticsNASDAQ:GYREView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 5,964,510 shares on 8/19/2024Ownership: 9.535%Samlyn Capital LLCBought 3,774,658 shares on 8/14/2024Ownership: 9.789%Marshall Wace LLPBought 74,559 shares on 8/14/2024Ownership: 0.119%Cubist Systematic Strategies LLCBought 24,364 shares on 8/14/2024Ownership: 0.039%Renaissance Technologies LLCSold 73,100 shares on 8/9/2024Ownership: 0.902%View All Insider TransactionsView All Institutional Transactions CRVS Stock Analysis - Frequently Asked Questions How have CRVS shares performed this year? Corvus Pharmaceuticals' stock was trading at $1.76 on January 1st, 2024. Since then, CRVS stock has increased by 140.3% and is now trading at $4.23. View the best growth stocks for 2024 here. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Top institutional investors of Corvus Pharmaceuticals include Samlyn Capital LLC (9.79%), Point72 Asset Management L.P. (9.54%), Renaissance Technologies LLC (0.90%) and Towerview LLC (0.64%). Insiders that own company stock include Richard A Md Miller, William Benton Jones, Leiv Lea, Linda Grais, Orbimed Advisors Llc and Ecor1 Capital, Llc. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN) and SCYNEXIS (SCYX). This page (NASDAQ:CRVS) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
